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______________________________________________________________________________ 
Background: Branched-chain keto acid 
dehydrogenase kinase (BDK) deficiency 
reduces branched chain amino acids and 
causes epilepsy with autistic features.  
Results: Loss of general control 
nonderepressible 2 (GCN2) in BDK-/- mice 
results in a fatal leukodystrophy.  
Conclusion:  GCN2 is essential for protecting 
glial cells during amino acid deficiency. 
Significance:  This study contributes novel 
information towards understanding the 
heterogeneous basis of white matter diseases.   
Abstract 
Branched chain amino acid (BCAA) 
catabolism is regulated by branched-chain 
alpha-keto acid dehydrogenase (BCKD), an 
enzyme complex that is inhibited when 
phosphorylated by its kinase (BDK).  Loss of 
BDK function in mice and humans causes 
BCAA deficiency and epilepsy with autistic 
features.  In response to amino acid 
deficiency, phosphorylation of eukaryotic 
initiation factor 2 alpha (eIF2~P) by general 
control nonderepressible 2 (GCN2) activates 
the amino acid stress response (AAR).  We 
hypothesized that GCN2 functions to protect 
the brain during chronic BCAA deficiency.  
To test this idea, we generated mice lacking 
both GCN2 and BDK (GBDK) and examined 
the development of progeny.  GBDK mice 
appeared normal at birth, but soon stopped 
growing, developed severe ataxia, tremor and 
anorexia, and died by postnatal day 15.  
BCAA levels in brain were diminished in 
both BDK-/- and GBDK pups.  Brains from 
BDK-/- pups exhibited robust eIF2~P and 
AAR induction, whereas these responses 
were absent in GBDK mouse brains.  Instead, 
myelin-deficiency and diminished expression 
of myelin basic protein were noted in GBDK 
brains.  Genetic markers of oligodendrocytes 
and astrocytes were also reduced in GBDK 
brains in association with apoptotic cell death 
in white matter regions of the brain.  GBDK 
brains further demonstrated reduced SOD2 
and catalase mRNA and increased TNFα 
mRNA expression. The data are consistent 
with the idea that loss of GCN2 during 
BCAA deficiency compromises glial cell 
defenses to oxidative and inflammatory 
stress.  We conclude that GCN2 protects the 
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brain from developing a lethal 




In mammals, the branched-chain 
amino acids (BCAA) leucine, isoleucine and 
valine are classified as nutritionally 
indispensable (i.e., dietary essential) amino 
acids.  BCAA comprise about 40% of the 
indispensable amino acid intake.  Leucine in 
particular can stimulate protein synthesis and 
can also regulate satiety and glucose 
metabolism through peripheral and central 
mechanisms.  Given the physiological 
importance of the BCAA in regulating protein 
and energy metabolism, it is a cellular priority 
to maintain plasma and tissue concentrations 
of BCAA within a relatively narrow range. 
This is accomplished through a highly 
regulated catabolic pathway involving the 
branched-chain ketoacid dehydrogenase 
(BCKD) enzyme complex.  Loss-of-function 
mutations in BCKD result in excess levels of 
BCAA which are neurotoxic, as demonstrated 
in maple syrup urine disease (1). 
Chronically elevated BCAA oxidation 
is also problematic.  BCKD enzyme activity is 
strongly inhibited by phosphorylation of its 
E1α subunit.  This mode of regulation is 
physiologically important, as verified by a 
~50% decrease in plasma and tissue BCAA 
levels in BCKD kinase (BDK) knockout mice 
(2).  BDK null (BDK-/-) mice exhibit impaired 
growth and neurological symptoms that 
include hindlimb clasping early in life and 
epilepsy later in life (2).  Interestingly, loss-of-
function mutations in the BDK gene in 
humans reduce plasma BCAA and cause 
intellectual disability and epilepsy in 
consanguineous families with autism spectrum 
disorders (3).  These reported neurological 
abnormalities in mice and humans indicate 
that properly-regulated BCAA metabolism is 
essential for healthy brain development and 
function. 
Mammalian cells respond to amino 
acid deficiencies by activating the amino acid 
stress response (AAR) featuring 
phosphorylation of the α subunit of eukaryotic 
initiation factor 2 (eIF2) by the protein kinase 
GCN2. (4). Phosphorylation of eIF2 alpha 
(eIF2~P) triggers a reduction in the guanine 
nucleotide exchange activity of eIF2B, stalling 
delivery of the initiator tRNA to the ribosome.  
As a consequence, general protein synthesis is 
repressed, lowering expenditure of nutrients 
and energy.  Coincident with a global 
reduction in protein synthesis, eIF2~P also 
leads to preferential translation of select 
mRNAs encoding transcription factors, such 
as activating transcription factor 4 (ATF4).  
ATF4 directly enhances the transcriptional 
expression of genes involved in the synthesis, 
transport and metabolism of amino acids, and 
boosts antioxidant defense capacity, providing 
cells the means to restore a healthy state (5). 
Studies of GCN2 null (GCN2-/-) mice 
demonstrate essential roles of the GCN2-
mediated AAR in food selection, growth and 
survival (6-9), hepatic lipid metabolism (10), 
and immune function (11,12).  Additionally, 
GCN2 facilitates the ability of single amino 
acid deprivation to mediate resistance to 
ischemic damage in renal and liver tissues 
elicited by surgical reperfusion in mice (13). 
In response to enhanced BCAA 
catabolism in BDK-/- mice, eIF2~P is 
markedly elevated in brain but not in other 
tissues (2).  Given the role of GCN2 in 
cellular protection during amino acid 
deficiency, we hypothesized that eIF2~P and 
the AAR serve to alleviate cellular stress and 
potential injury caused by BCAA deprivation.  
Consequently, a loss of GCN2 function would 
be detrimental to the BDK-/- mouse brain.  To 
test this hypothesis, we crossed GCN2-/- mice 
with those deleted for BDK to generate GCN2-
BDK double knockout (GBDK) mice.  We 
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found that the GCN2-initiated AAR was 
active in the brain of BDK-/- mice but not in 
GBDK mice.  Although born normal in size 
and appearance, GBDK mice soon declined in 
neurological function and locomotor control, 
exhibiting tremor, ataxia and a general failure 
to develop and thrive.  In this study, we reveal 
the mechanism for the neurological 
deterioration observed in GBDK mice. These 
discoveries reflect the essential role of GCN2 
to protect the cell types and processes 
necessary for postnatal myelin formation and 
brain development. The genetic mouse model 
and cellular pathways described herein 
contributes novel information towards 
understanding the heterogeneous mechanisms 
responsible for leukodystrophy and other 
white matter diseases. 
EXPERIMENTAL PROCEDURES 
Animals. The following study protocol 
was approved by the Institutional Care and 
Use Committees at the Indiana University
School of Medicine-Evansville and at Rutgers, 
The State University of New Jersey.  Mice 
were housed in plastic shoebox cages with soft 
bedding and provided social enrichment. Mice 
were given unrestricted access to standard 
commercial rodent food (7017 NIH-31 Open 
Formula Mouse/Rat Sterilizable diet, Harlan 
Teklad) and tap water and maintained on a 12 
h light:dark cycle.  To generate GBDK mice, 
GCN2-/- female mice were mated with BDK-/- 
male mice (both on C57BL/6J genetic 
background for at least 8 generations), 
generating GCN2+/-•BDK+/- offspring.  These 
offspring were brother-sister mated, and 
progeny expressing GCN2-/-•BDK+/- were 
again brother-sister mated to generate litters 
containing GBDK pups.  In addition, GCN2+/+ 
• BDK+/- males and females were mated to
produce GCN2+/+ • BDK+/+ wildtype (WT) 
mice and GCN2+/+ • BDK-/- (BDK-/-) mice.  
Blood samples were collected after 
decapitation, and whole brains were quickly 
removed and snap-frozen in liquid nitrogen.   
Whole blood measurements. Blood 
glucose was measured using the 
CardioChekTM System (Polymer Technology 
Systems, Inc., Indianapolis, IN).  Hematocrit 
was determined by collecting whole blood in a 
capillary tube and calculating the percentage 
of packed red blood cell volume following 
centrifugation. 
Amino acid analyses. Whole pups at 
age P1 and P7 were euthanized, and the 
gastrointestinal tract of pups at P1 and P7 
were removed. Pups were snap-frozen and 
ground to a fine powder with a mortar and 
pestle under liquid nitrogen. Frozen powder 
was weighed and extracted with 3 volumes of 
6% (w/v) perchloric acid for deproteinization. 
Precipitated proteins were removed by 
centrifugation, and the supernatants were 
neutralized with 20% potassium hydroxide. 
Concentrations of BCAA and total amino 
acids in whole-body were measured using 
high performance liquid chromatography 
(HPLC) as previously described (14).  
Concentrations of amino acids in whole brain 
were analyzed by Kristine C. Olson under the 
supervision of Dr. Christopher J. Lynch  (15). 
Free amino acids were pre-column derivatized 
using Phenomenex EZ-fast reagent and 
analyzed by UPLC-MS using a Waters Synapt 
HDMS hybrid QTOF with Ion Mobility, 
located in the Penn State College of Medicine 
Macromolecular Core Facility. 
Immunoblot analysis. Tissues were 
processed for SDS-PAGE and 
immunoblotting as previously described 
(6,16).  Primary antibody for eIF2α 
phosphorylated at serine 51 was purchased 
from Cell Signaling Technology (Beverly, 
MA). Antibody for total eIF2α was purchased 
from Santa Cruz Biotechnology. Eukaryotic 
initiation factor 4E-binding protein 1 (4E-
BP1) antibody was obtained from Bethyl 
Laboratories and myelin basic protein 
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antibody was from Millipore (Billerica, MA). 
Polyclonal antibodies against the E1 alpha and 
E2 subunits of the BCKD complex were 
prepared in the Harris laboratory (2).  
Secondary antibodies were purchased from 
Jackson ImmunoResearch (West Grove, PA). 
Protein expression was visualized using 
enhanced chemiluminescence reagents (ECL; 
GE Biosciences, Piscataway, NJ) and 
analyzed using a Carestream 4000MM or Gel 
Logic 6000 image station and molecular 
imaging software (Carestream Health, 
Rochester, NY). 
Reverse transcription and Real-
Time PCR. Total RNA was extracted from 
frozen tissue as previously described using 
TriReagent (Molecular Research Center, Inc., 
Cincinnati, OH) (17), and 1 μg of RNA per 
sample was used for reverse transcription 
(RT) using High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster 
City, CA, USA) according to the 
manufacturer's instructions. TaqMan Gene 
Expression Master Mix and TaqMan Gene 
Expression Assays (Applied Biosystems) were 
used for qPCR. Amplification and detection 
were performed using the StepOnePlus Real-
Time PCR System (Applied Biosystems).  All 
measurements were performed in triplicate 
and normalized to 18S ribosomal RNA. 
Results were obtained by the comparative Ct 
method, and results were expressed as fold 
change with respect to the experimental 
control. 
Histology. To stain myelinated axons, 
whole brains fixed in 4% paraformaldehyde 
were bisected at the mid-sagittal plane and 
incubated in a clear glass vial at 37ºC for 2 
hours in 10 ml of a 0.2% gold chloride 
solution (per L: 1.8 g crystalline gold chloride, 
0.33 g sodium phosphate monobasic 
monohydrate, 3.6 g sodium phosphate dibasic 
anhydrous, 9.0 g sodium chloride) as 
previously reported (18,19).  Stained material 
was then transferred to 20 ml of 2.5% sodium 
thiosulfate anhydrous for 5 min before storage 
in fresh 4% paraformaldehyde kept in the 
dark.   Additional cuts were made in the 
coronal plane and re-stained, as well as tissues 
sections in both the sagittal and coronal 
planes.  Frozen sections (16 µm) were 
obtained from whole and half brains fixed in 
4% paraformaldehyde using a cryostat. 
TUNEL assays were performed on frozen 
sections using a TACS-XL® In Situ Apoptosis 
Detection Kit (R&D Systems, Minneapolis, 
MN) as previously described (11). 
Statistics. Data were analyzed using 
two-way analysis of variance (StatSoft, Tulsa, 
OK) to assess main effects, with GCN2 and 
BDK as independent variables in some 
instances and genotype and time as 
independent variables in other situations. In 
cases where a two-way ANOVA was not 
possible, a one-way ANOVA was performed 
with genotype as the independent variable. 
When a significant overall effect was detected, 
differences among treatment groups were 
assessed with LSD’s post-hoc test. The level 
of significance was set at P < 0.05 for all 
statistical tests. 
RESULTS 
GBDK mice display neurological 
abnormalities and early death.  To 
understand the physiological importance of 
GCN2-directed eIF2~P in the brains of BDK-/- 
mice, we bred BDK-/- mice to GCN2-/- mice so 
as to create a GBDK double homozygous null 
strain. Genotype analysis of newborn 
offspring from GCN2-/-•BDK+/- breeders 
showed the targeted alleles were present in the 
expected Mendelian frequency.  Of the 116 
one-day old pups generated from GCN2-/-
•BDK+/- cross, 32, 56 and 28 were GCN2-/-
•BDK+/+, GCN2-/-•BDK+/-, and GCN2-/-•BDK-/-
pups, respectively.  However, no GCN2-/-
•BDK-/- offspring were found in litters weaned
at postnatal day (P) 28, suggesting early 
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postnatal death of GBDK pups.  The GBDK 
phenotype was monitored from birth until 
natural death by recording general appearance 
and behavior as well as measuring body 
weight.  GBDK null pups were 
indistinguishable from littermates at birth. 
Some newborn GBDK pups died within 72 
hours after birth; these losses were usually 
attributed to maternal neglect of the whole 
litter.  GBDK pups surviving the first few 
days of life later displayed light coat color, 
frequent shaking/tremors, splayed limbs, and 
social isolation.  As shown in the 
accompanying video (see Supplemental 
Movie 1), GBDK pups at P10 had difficulty 
maintaining normal gait and posture, 
displaying ataxia, tremors and splayed limbs.  
By P11-14, as a consequence of progressive 
seizure activity, immobility and weakness, the 
GBDK pups experienced natural death.  No 
GBDK pups survived past P15. In contrast, 
heterozygous GCN2-/-•BDK+/- mice were 
indistinguishable from GCN2-/-•BDK+/+ mice 
and showed similar behavior, body and organ 
weighs and blood glucose levels (Fig. 1). 
Impaired growth, decreased food 
intake and hypoglycemia in GBDK mice.  
GBDK pups had normal body weight at birth 
and at P4 (Fig. 1A and 1B).  However, the 
body weight of GBDK was 22% and 58% 
lower by P7 and P11, respectively, compared 
with GCN2-/-•BDK+/+ pups, indicating 
severely impaired growth (Fig. 1B).  All 
GBDK organ weights at P11 were 
significantly reduced in size except for brain 
which was increased as compared to GCN2-/-
•BDK+/+ pups (Fig. 1C).  However, this
increase reflected a wasted condition, as the 
absolute brain weight of GBDK pups was 
~50% lower than GCN2-/-•BDK+/+ controls 
(data not shown). 
  The decreased body weight of the 
GBDK pups led us to investigate food intake.  
All pups had comparable amounts of milk in 
their stomachs at P4; however all GBDK pups 
had empty stomachs at P11-14.  Even at P7-8, 
some GBDK pups had little to no milk in their 
stomachs.  Consistent with decreased body 
weight and food intake, GBDK mice were 
hypoglycemic at P7 and P11 (Fig. 1D).  Blood 
glucose concentrations were decreased 63% 
and 75%, respectively, whereas glucose levels 
did not differ from GCN2-/-•BDK+/+ pups at 
P1 and P4. Hepatic PEPCK mRNA abundance 
at P11 was increased 4-fold in GBDK mice 
compared with GCN2-/-•BDK+/+ mice (data 
not shown), suggesting that hypoglycemia was 
not caused by reduced gluconeogenic 
capacity.  Blood glucose concentrations in 
prefed and fed pups at P1 did not differ 
between GBDK and GCN2-/-•BDK+/+  mice, 
although blood glucose was ~40% lower in 
prefed than fed pups at P1 regardless of 
genotype (data not shown).  These data 
suggest that the GBDK pups gradually 
decreased food intake as they began to exhibit 
severe neurological deficits. 
Brain concentrations of amino acids 
are significantly altered in BDK-/- and 
GBDK mice.  First, to confirm BDK deletion 
in GBDK pups, we used Western blot to 
measure BCKD E1α and E2 protein and 
phosphorylation state in the brain (Fig. 3A).  
Previous investigations showed that the 
electrophoretic mobility of E1α is reduced 
when phosphorylated (20,21) and 
electrophoretic migration of the E1α subunit is 
significantly faster in BDK-/- mice (2).  
Consistent with these reports, brain samples 
from GBDK and BDK-/- mice showed reduced 
phosphorylation of E1α, suggesting elevated 
BCKD activity and increased BCAA 
catabolism.  To determine how the combined 
loss of GCN2 and BDK affected amino acid 
concentrations, whole body BCAA and total 
amino acid levels were measured at P1 and 
P7.  At P1, whole-body BCAA levels in 
GBDK and GCN2-/-•BDK+/- pups were 
decreased by 50 and 39%, respectively, 
indicating that BDK-regulated BCAA 
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catabolism occurs at a very early age (Fig. 
2A).  At P7, whole-body BCAA levels in 
GBDK mice remained 37% lower than GCN2-
/-•BDK+/+ mice whereas BCAA levels in 
GCN2-/-•BDK+/- and GCN2-/-•BDK+/+ mice 
were similar.  Total amino acids did not differ 
among the three mutant strains at either P1 or 
P7 (Fig. 2B). 
Next, whole-brain amino acids were 
measured in GBDK, BDK-/-, GCN2-/-, and WT 
mice at P6 (Table 1).  This day was chosen to 
avoid the effect of decreased food intake 
observed after P7 in GBDK pups.  The sum of 
brain leucine, isoleucine and valine did not 
differ between GCN2-/- and WT mice.  By 
comparison, BCAA concentrations in BDK-/- 
and GBDK brains were lowered ~50-80%, 
consistent with a ~70 % decrease reported in 
adult mice (2) and a ~50% decrease reported 
in P14 pups (3).  Also consistent with previous 
work, most amino acids were significantly 
elevated 2 fold or more in BDK-/- brains, with 
glycine showing a nearly 5-fold elevation as 
compared to WT.  Surprisingly, nearly all 
amino acid increases identified in BDK-/- 
brains were not present in GBDK brains.  
Except for aspartate, the BCAA, and 
phenylalanine, all amino acid concentrations 
in GBDK were statistically similar to WT. 
The AAR is activated in the brains 
of BDK-/- but not GBDK mice.  Activation of 
GCN2 and the AAR upregulates genes 
involved in amino acid synthesis, metabolism 
and transport (5,22). As such, we 
hypothesized that the differences in brain 
amino acid concentrations between BDK-/- and 
GBDK mice were due to a differentially-
activated AAR. 
To assess this, eIF2~P was measured. 
As expected, eIF2~P was increased in the 
brain of BDK-/- mice as compared with WT 
controls (Fig. 3B).  However, eIF2~P was not 
increased in the brains of GBDK mice, despite 
diminished BCAA levels.  We next measured 
mRNA expression of several downstream 
targets of the GCN2-directed AAR pathway in 
whole brain lysates (Fig. 3C). As we and 
others have detailed previously (22,23), 
eIF2~P promotes gene-specific translation of 
ATF4 which serves as a  transcriptional 
activator of itself and many other genes 
including ATF5, asparagine synthetase 
(ASNS), and CAAT enhancer binding protein 
homologous protein (CHOP).  Consistent with 
this, mRNA abundance of ATF4, ATF5, ASNS 
and CHOP were increased in the brains of 
BDK-/- mice over 2-fold as compared to WT.  
In contrast, mRNA expression of ATF4, 
ATF5, ASNS and CHOP in the brains of 
GCN2-/- and GBDK mice were reduced ~50% 
as compared with WT. In addition, gene 
expression of the ER chaperone BiP/GRP78, a 
marker of ER stress, was not increased in 
BDK-/- mice and was further decreased in 
GBDK mice (Fig. 3C). 
Amino acid deficiency reduces 
phosphorylation of the translational repressor 
eIF4E binding protein 1 (4E-BP1), stalling 
translation initiation. ATF4 expression 
induces 4E-BP1 transcription in beta cells 
during ER stress (24).  Increased 4E-BP1 
expression alongside 4E-BP1 
hypophosphorylation can serve to maximally 
inhibit mRNA translation.  By contrast, 
hyperphosphorylation of 4E-BP1 liberates it 
from eIF4E and thereby facilitates binding of 
eIF4E with eIF4G, leading to cap-dependent 
translation initiation of many mRNAs.  In the 
brains of BDK-/- mice, 4E-BP1 mRNA and 
protein expression was increased together 
(Fig. 3C and 3D upper panel) alongside 
reduced 4E-BP1 phosphorylation (Fig. 3D 
lower panel).  Importantly, these outcomes 
were abolished in the brains of GBDK mice 
suggesting that 4E-BP1 activity is enhanced 
by GCN2 and the AAR. 
Amino acids including BCAA are 
competitively transported across the blood-
brain barrier by Slc7a5/Slc3a2 (LAT1), and, 
to a lesser extent, by members of the y+-type 
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family and the Na+-dependent large neutral 
amino acid transporter (25). Given the marked 
alterations in brain amino acid concentrations 
in both BDK-/- and GBDK mice, and the 
knowledge that amino acid transporters such 
as Slc7a1 are known targets of ATF4 (26), we 
next measured mRNA expression of the 
heterodimeric Slc7a5/Slc3a2 (LAT1), the 
major L-system transporter, and Slc7a1 
(CAT1), a major y+-system transporter in brain 
lysates (Fig. 3E).  Whereas Slc3a2 mRNA 
abundance was similar across genetic strains 
of mice, the levels of Slc7a5 and Slc7a1 
encoding transcripts increased ~30% and 
~70%, respectively, in BDK-/- brain lysates as 
compared to WT.  In contrast, mRNA 
expression of Slc7a1 and Slc7a5 did not 
increase in the brain of GBDK mice and 
remained similar to WT mice. These data are 
consistent with the idea that activation of the 
AAR by GCN2 promotes increased flux of 
AA into the brain of BDK-/- mice. 
Hypomyelination in brains of GBDK 
mice.  Brains of GBDK mice collected at 
postnatal day P1, 4, 8, and 11 were examined 
and found to be lighter, softer and more fragile 
at P8 and P11 as compared with littermates.  
These macroscopic traits are reported in white 
matter disorders such as vanishing white 
matter disease /childhood ataxia with central 
nervous system hypomyelination 
(VWMD/CACH) syndrome. This syndrome is 
caused by missense mutations in the genes 
encoding the subunits of eIF2B that reduce 
exchange of eIF2-GDP to eIF2-GTP in eIF2 
(27,28).  In fact, a number of fatal 
hypomyelinating conditions exhibit 
neurological symptoms of seizures, action 
tremor, spasticity, weakness, and cerebellar 
ataxia similar to GBDK mice.  We thus used a 
specific histological staining method to 
qualitatively examine myelin in whole brains.  
Frozen sections of brain were stained in both 
the coronal and sagittal planes with gold 
chloride to visualize myelin as previously 
described (18,19).  We first performed en bloc 
staining of bisected brains which revealed less 
myelin in sagittal hemispheres of brains of 
GBDK mice (Fig. 4A).  Brains from GCN2-/- 
pups were more darkly stained with gold 
chloride than GBDK at postnatal day 11, 
especially the corpus callosum and 
hippocampal formation, regions of abundant 
white matter.  Moreover, structural differences 
were noted in that the cerebellum and 
hippocampus in GBDK brains were 
proportionately smaller as compared with 
GCN2-/- mice, consistent with decreased 
myelination and ataxia exhibited in these 
mice.  We further examined coronal frozen 
brain sections stained with gold chloride under 
light microscopy (Fig. 4B).  In the brains of 
GCN2-/- mice, many dark filament-like 
structures were seen; under higher 
magnification, there were both darkly stained 
large myelinated bundles and fine individually 
myelinated fibers in corpus callosum and 
hippocampal formation.  However, in GBDK 
brains, these myelinated structures were less 
abundant and stained markedly lighter. 
GBDK mice display reduced 
oligodendrocyte development and survival.  
Myelin is synthesized by oligodendrocytes, 
which originate from migratory and mitotic 
precursors that mature progressively into 
postmitotic myelin-producing cells (29).  We 
measured expression of molecular markers of 
oligodendrocyte precursors and maturation to 
evaluate oligodendrocyte development in the 
brains of the WT and mutant mice (Fig. 5A).  
The basic helix-loop-helix transcription 
factors Olig1/2 play a crucial role in 
oligodendrocyte differentiation and 
myelination as well as remyelination (30-32).  
The abundance of Olig2 mRNA, a marker of 
oligodendrocyte precursor cells (OPC), was 
moderately decreased in BDK-/- brains and 
further decreased in GBDK brains as 
compared with WT.  By contrast, the 
abundance of platelet-derived growth factor 
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receptor alpha (PDGFRα) mRNA, whose gene 
product reportedly drives OPC division (33) 
was unaltered.  Genetic markers of mature, 
myelinating oligodendrocytes were then 
examined. Transcript levels of the two major 
myelin proteins, myelin basic protein (MBP) 
and proteolipid protein (PLP1), as well as 
mRNAs encoding for myelin oligodendrocyte 
glycoprotein (MOG) were significantly 
decreased in brains of GBDK mice.  
Transcript levels of these markers in the brains 
of BDK-/- and GCN2-/- mice were similar to 
WT mice. 
Consistent with decreased MBP 
mRNA expression, MBP protein content in 
brain was markedly diminished in GBDK 
mice as compared with BDK-/- and GCN2-/- 
mice (Fig. 5B).  Further investigation of the 
developmental regulation of MBP protein 
levels in brains of mice showed that MBP 
protein was difficult to detect before P8, but 
MBP was robustly expressed at P11-14 (Fig. 
5C).  In contrast, expression of MBP protein 
was barely detectable in GBDK brains at P11-
14. Together, these results suggest that
GBDK mice suffered defective development 
of the myelin sheath in association with less 
oligodendrocyte populations. 
To determine whether neurons or other 
glial cell types were also impacted with loss of 
BDK and GCN2, we measured gene 
expression of Nevrod6 (marker of neurons) as 
well as GFAP and AQP4 (markers of 
astrocytes) (Fig. 5A).  Messenger RNA levels 
of both GFAP and Nevrod6 were similar 
among WT, GCN2-/-, BDK-/-, and GBDK 
brains, whereas the amounts of AQP4 
transcripts were reduced ~40% in GBDK as 
compared with WT brains.  Thus, in the 
absence of GCN2, severe BCAA deficiency is 
detrimental to the development of myelin in 
association with an apparent loss of glial cells 
and especially mature oligodendrocytes. 
Diminished oxidative defense in 
combination with neuroinflammation are 
associated with increased apoptosis in 
GBDK brains.  To assess if the defect in 
myelin formation was due to a decrease in the 
survival of developing oligodendrocytes, 
tissue sections were stained for the presence of 
apoptosis via TUNEL assay.  The presence of 
pyknotic nuclei was identified in regions 
containing white matter in GBDK brains (Fig. 
6A).  While the full range of cell types 
undergoing apoptosis remains to be identified, 
the supporting data are consistent with the 
idea that glial cells and especially the 
oligodendrocyte populations are undergoing 
premature cell death in response to loss of 
GCN2 during BCAA deficiency. 
Because of the complex differentiation 
program as well as their unique metabolism, 
oligodendrocytes are among the most 
vulnerable cells of the central nervous system 
(34).  Oligodendrocyte precursors are more 
susceptible to oxidative stress than other glial 
cell types (35).  Cytokines produced by glial 
cells also significantly impact oligodendrocyte 
function and are linked to inflammatory white 
matter disorders (36). To begin to elucidate 
the mechanisms underlying the premature 
death of oligodendrocytes, we measured 
mRNA expression of key genes involved in 
antioxidant defense and inflammatory stress. 
First, mRNA expression of superoxide 
dismutase 2 (SOD2) and catalase (CAT) in the 
brain of GBDK mice was reduced 40-50% as 
compared to WT (Fig. 6B), suggesting that 
antioxidant defenses were compromised.   
Second, while whole brain mRNA expression 
of inflammatory cytokines IL6 and IL1β were 
low in WT and mutant mice (data not shown), 
there was a ~3-fold increase in mRNA 
encoding TNFα  in the brain of GBDK mice 
as compared to WT (Fig. 6C).  Collectively, 
these results are consistent with the idea that 
during chronic BCAA deficiency, loss of 
GCN2 predisposes the neonatal glia toward 
injury by oxidative and inflammatory stress. 
GCN2 protects white matter in brain during amino acid stress 
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DISCUSSION 
Loss-of-function defects in the BDK 
gene result in epilepsy in humans and mice 
and incite neurological features identified in 
autism-spectrum disorders (2,3). These 
clinical observations alongside the reported 
increase in eIF2~P in the brains of BDK-/- 
mice (2) prompted us to address the role of 
GCN2 in the protection of neurological 
functions during BCAA deficiency.  To this 
end, we generated mice deficient in BDK and 
GCN2 and discovered a lethal outcome 
involving the interruption of myelin formation 
alongside symptoms and pathology 
reminiscent of white matter disease.  The 
leukodystrophy identified correlated with 
evidence suggesting oxidative and/or 
inflammatory injury of oligodendrocytes and 
other glial cell types.  Collectively, our results 
suggest that the GCN2-AAR functions to 
prevent or minimize white matter injury 
during amino acid stress. 
GCN2-/- mice fed a standard chow diet 
have a normal phenotype.  In contrast, BDK-/- 
mice fed chow exhibit growth retardation and 
neurological abnormalities that include 
hindlimb flexion throughout life and epileptic 
seizures after 5 months of age (2).  While the 
growth defect and neurological symptoms in 
BDK-/- mice are reversible by feeding a high 
protein diet or dietary supplementation of 
BCAA (2,3), attempts to provide GBDK pups 
BCAA supplements did not increase 
survivability (unpublished observations). 
Indeed, compared with BDK-/- mice, GBDK 
mice are much more neurologically impaired, 
developing a severely maladaptive phenotype 
that culminates in death by 15 days of age. 
Various inborn errors of metabolism 
cause white-matter disease i.e. 
leukodystrophies (reviewed in (37)).  Defects 
in genes encoding the 5 subunits of the 
guanine nucleotide exchange factor eIF2B 
also result in a spectrum of white matter 
diseases and other neuropathies (38).  Many of 
these diseases associate with ER stress and 
activation of the unfolded protein response 
(27,28).  From this vantage point, the GBDK 
mouse is both clinically important and 
mechanistically unique. With respect to the 
former, the pathology described contributes 
importantly to a growing list of white matter 
diseases linked to defects in the translation 
initiation machinery.  With respect to the 
latter, activation of the GCN2-mediated AAR 
but not ER stress in the BDK-/- brain 
emphasizes the importance of regulating 
eIF2~P during postnatal brain development. 
Furthermore, based on our current data, we 
argue that brain trauma and stress without 
eIF2~P produces greater brain injury, and that 
activation of eIF2~P in the brain by GCN2 is 
inherently cytoprotective. 
The process of myelination in the 
central nervous system is carried out by the 
mature oligodendrocytes. In mouse brain, 
myelination is achieved in almost all regions 
by around 45–60 days after birth.  The timing 
of CNS myelination is characterized by 
precise regulation of oligodendrocyte 
differentiation and proliferation (29).  
Preceding myelination, myelin specific genes 
are activated, and mature non-myelinating 
oligodendrocytes express MBP, PLP, and 
MOG (29).  Hypomyelination is found in the 
PLP null (‘jimpy’) mouse and MBP null 
(‘shiverer’) mouse as well as the “Taiep” [an 
acronym for trembling, ataxia, immobility 
episodes, epilepsy, and paralysis] rat (39-41). 
These rodent models all exhibit neurological 
symptoms resembling the GBDK mice, in 
agreement with markedly decreased protein 
and mRNA levels of PLP1 and MBP.  
Myelinating mature oligodendrocytes develop 
from progenitors that display characteristic 
genetic markers at each developmental stage. 
Among the earliest markers to be expressed is 
PDGFRα mRNA which in the current study 
was found unaltered in GBDK brains.  On the 
other hand, the level of Olig2 mRNA, a 
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marker highly expressed in proliferating 
immature oligodendrocytes, was significantly 
reduced in expression in GBDK mice. These 
findings, in combination with reduced MBP, 
PLP1 and MOG mRNAs suggests that the 
developing oligodendrocyte progenitors are 
the cell populations most affected in GBDK 
brains. 
Oligodendrocyte progenitor cells are 
extremely susceptible to oxidative stress and 
oxidative defense genes such SOD2 and 
GPX1 confer protection against oxidative 
injury in developing oligodendrocytes (42,43).  
In the current study, mRNAs encoding brain 
SOD2 and catalase were decreased in GBDK 
mice, consistent with reports suggesting that 
GCN2 and eIF2~P are redox regulators 
protecting against oxidative stress (5,44,45). 
Oxidative stress and pro-inflammatory 
cytokines are found to contribute to 
demyelination and axonal damage in cultured 
cerebellar cells and promote oligodendrocyte 
progenitor cell death in microglia treated with 
LPS (46,47). It is also reported that microglia 
and astrocytes produce and secret TNFα, 
inhibiting the survival and differentiation of 
oligodendrocyte precursor cells (48,49).  
Consistent with these reports, a marked 
increase in TNFα mRNA level was detected in 
GBDK brains, suggesting a pro-inflammatory 
environment. Although the mechanistic details 
underlying increased TNFα in GBDK brains 
remain to be revealed, our data are consistent 
with the idea that increased oxidative and 
inflammatory stress contribute to the loss of 
oligodendrocytes in GBDK mice.   
In agreement with previous reports 
(2,3), BDK-/- brain lysates demonstrated 2-5 
fold increases in most amino acids alongside 
profound reductions in BCAA concentrations. 
Interestingly, while brain BCAA 
concentrations remained significantly reduced 
in GBDK mice, concentrations of most other 
amino acids returned to values similar to WT 
mice (Table 1).  While the reasons for the 
elevation in amino acids in BDK-/- brain and 
the reversal of brain amino acid levels in 
GBDK mice are unclear, speculation is 
offered.  The simplest unifying explanation is 
that activation of the GCN2-AAR upregulates 
genes involved in amino acid synthesis, 
metabolism and transport, resulting in a net 
increased flux of amino acids into the brain. 
Supporting this idea, Slc7a1 mRNA 
abundance was elevated in BDK-/- brain in a 
GCN2-dependent fashion (Figure 3E). On the 
other hand, mRNA expression of Slc7a5 and 
Slc3a2 was not influenced by GCN2 status. 
Thus, future studies are needed to clarify the 
contribution of AAR activation to amino acid 
metabolism and neurotransmitter signaling in 
the brain during nutrient stress. 
Glutamate, the most abundant 
excitatory neurotransmitter in the mammalian 
brain, is an antimitotic signal at all 
proliferative stages of the oligodendrocyte 
lineage (50,51).  It is proposed that glutamate 
concentrations in astrocytes and neurons are in 
part regulated through a leucine-glutamate 
cycle (52). In the current study, brain 
glutamate concentrations were unaltered in 
both BDK-/- and GBDK mice.  Considering 
that tissue lysates cannot reveal dynamic 
changes in cellular flux within or between cell 
types, future studies are needed to determine 
the relationship between AAR activation and 
the flux of neurotransmitters such as 
glutamate. 
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Table 1. Whole brain amino acid concentrations (nmol/g tissue) in pups on postnatal day 6. 
WT BDK-/- GCN2-/- GBDK 
Leucine 46.0 ± 6.5a 7.8 ± 0.9c 31.8 ± 4.4ab 20.7 ± 7.1bc 
Isoleucine 24.8 ± 4.3a 4.6 ± 1.0c 18.6 ± 2.9ab 11.2 ± 5.7bbc 
Valine 40.7 ± 2.3a 10.6 ± 2.5b 42.7 ± 6.8a 20.6  ± 5.5b 
Threonine 153.7 ± 7.6b 487.5 ± 44a 171.0 ± 14.3b 176.1 ± 5.8b 
Phenylalanine 27.7 ± 5.6b 29.0 ± 6.9ab 15.5 ± 3.2b 52.6 ± 12.9a 
Tyrosine 38.6 ± 8.6b 128.7 ± 13.3a 42.0 ± 4.4b 61.7 ± 14.4b 
Histidine 55.0 ± 3.0b 107.1 ± 9.8a 56.3 ± 3.3b 62.9 ± 11.2b 
Methionine 39.3 ± 8.8b 60.0 ± 4.7a 37.0 ± 4.1b 44.1 ± 9.4b 
Serine 544.5 ± 19.4b 954.5 ± 62.1a 611.3 ± 73.8b 481.3 ± 102.7b 
Glycine 569.2 ± 37.2b 2628.4 ± 234.1a 672.6 ± 52.8b 490.4 ± 61.7b 
Lysine 128.2 ± 10.6a 130.2 ± 9.5a 70 ± 14.8b 114.4 ± 19.8a 
Ornithine 13.8 ± 0.4b 24.8 ± 1.7a 12.4 ± 2.0b 11.6 ± 1.6ab 
Arginine 33.5 ± 1.9b 93.9 ± 7.8a 27.2 ± 3.4b 47.6 ± 12.1b 
Glutamine 1139.4 ± 86.5b 2447.9 ± 400.5a 1238 ± 167.7b 1699 ± 327.5ab 
Glutamate 1564.6 ± 166.2 1167.8 ± 66.7 1317.9 ± 169.1 1384.1 ± 288.2 
Proline 193.2 ± 7.2bc 427.1 ± 35.6a 241.5 ± 11.4b 142.8 ± 28.9c 
Alanine 264.8 ± 12.8b 490 ± 52.4a 257.8 ± 23.6b 170.4 ± 49.4b 
Aspartate 557.5 ± 38.6b 657.9 ± 34.3ab 556.2 ± 71.8b 906.2 ± 149.6a 
Asparagine 41.1 ± 5.7b 96.0 ± 20.6a 36.1 ± 9.3b 21.6 ± 7.1b 
Tryptophan 12.6 ± 2.8 21.2 ± 3.0 12.1 ± 1.6 30.2 ± 11.7 
4-Hydroxyproline 60.8 ± 8.2b 157.4 ± 9.8a 61.4± 11.1b 64.3 ± 21.2b 
Citrulline 22.3 ± 3.7b 70.4 ± 9.7a 22.9 ± 3.4b 34.2 ± 7.2b 
Cystathionine 22.8 ± 1.0b 57.9 ± 3.4a 23.7 ± 1.4b 31.0 ± 5.1b 
Data are expressed as means ± SEM, n=5 per group. Means in a row without a common letter 
differ, P < 0.05. 
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FIGURE LEGENDS 
Figure 1. GBDK mice exhibit neurological abnormalities, growth-deficiencies and 
hypoglycemia 1-2 weeks after birth.  (A) Images of GCN2-/-•BDK+/+, GCN2-/-•BDK+/- and GBDK 
littermates at postnatal days 1, 7 and 11.  Body weights (B), organ weights (C), and blood 
glucose concentrations (D) in GCN2-/-BDK+/+, GCN2-/-BDK+/- and GCN2-/-BDK-/- pups at 
postnatal days 1, 4, 7 and 11.  Bars represent means ± SEM; n = 6-9 per group. Means without a 
common letter differ, P < 0.05. 
Figure 2. GBDK mice exhibit diminished whole-body BCAA concentrations at 1 and 7 days of 
age. Whole-body BCAA (A) and total amino acid concentrations (B) in GCN2-/-BDK+/+, GCN2-/-
BDK+/- and GCN2-/-BDK-/- littermates at postnatal days 1 and 7.  Bars represent means ± SEM; n 
= 6-9 per group. Means without a common letter differ, P < 0.05. 
Figure 3. GCN2 is required for activation of the amino acid stress response in the brains of BDK-
/- mice at postnatal day 11-14.  (A) Protein expression and phosphorylation state of the branched 
chain ketoacid dehydrogenase (BCKD) subunits E2 and E1α in brain lysates of WT, GCN2-/-, 
BDK-/- and GBDK mice. Note that phosphorylation (P) of E1α retards its electrophoretic 
mobility. (B) Phosphorylation of eIF2α subunit at serine 51 in brain lysates of WT, GCN2-/-, 
BDK-/- and GBDK mice. (C) Gene expression of ATF4, ATF5, CHOP, 4E-BP1, and BiP/GRP78 
mRNA in brain lysates of WT, GCN2-/-, BDK-/- and GBDK mice. (D) 4E-BP1 protein expression 
(upper) and phosphorylation (lower) in brain lysates of WT, GCN2-/-, BDK-/- and GBDK mice. 
(E) mRNA expression of Slc7a5, Slc3a2 (LAT1) and Slc7a1/CAT1 in brain lysates of WT, 
GCN2-/-, BDK-/- and GBDK mice. Bars represent means ± SEM; n = 4-8 per group. Means 
without a common letter differ, P < 0.05. 
Figure 4. GBDK mice demonstrate hypomyelination in white matter regions of the brain.  (A) 
Representative gold chloride staining of bisected sagittal hemispheres of brains imaged using a 
dissecting microscope set to 1X magnification.  (B) Representative coronal sections taken rostral 
to bregma using a dissecting microscope set to 2X magnification.  Higher magnification (200X) 
under a light microscope revealed the presence of myelin fibers in the corpus callosum and 
hippocampal formation.  Images are representative of 3 mice per genotype at postnatal days 11-
14. 
Figure 5. GBDK brains show diminished expression of oligodendrocytes alongside reduced 
myelin basic protein.  (A) mRNA expression of genes activated during oligodendrocyte 
development (Olig2, PDGFRα) and maturation (MBP, PLP1, MOG) as well as markers of 
neurons (Nevrod6) and astrocytes (GFAP, AQP4)  in WT, GCN2-/-, BDK-/- and GBDK mice at 
postnatal day 11-14. (B) Immunoblot analysis of myelin basic protein (MBP) in WT, GCN2-/-, 
BDK-/- and GBDK brain lysates at postnatal day 11-14.  Actin was used as an endogenous 
loading control.  (C). Immunoblot analysis of MBP in GCN2-/-•BDK+/+, GCN2-/-•BDK+/- and 
GCN2-/-•BDK-/- brain lysates at postnatal day 3, 8, 11-14.  Two-way ANOVA showed a 
significant effect of age, genotype and age x genotype interaction (P < 0.001). Bars represent 
means ± SEM; n = 4-10 per group. Means without a common letter differ, P < 0.05. 
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Figure 6. GBDK brains exhibit apoptotic nuclei in the hippocampus in association with 
diminished oxidative defense and increased inflammation.  (A) Frozen brains were sectioned in 
both the sagittal and coronal planes to assess DNA fragmentation by TUNEL assay.  Apoptotic 
nuclei (indicated by arrows pointing to blue stained cells in highlighted boxes) were identified in 
the hippocampus of GBDK but not WT brains at 200X magnification.  Results represent 3 mice 
per genotype at postnatal day 11-14.  (B) SOD2 and catalase mRNA levels are reduced in GBDK 
brain lysates. (C) Increased TNFα mRNA expression in GBDK brain lysates.  Bars represent 
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